HCWB HCW Biologics Inc.

FDA Catalyst Company
2.1
-0.01  0%
Previous Close 2.11
Open 2.18
52 Week Low 1.89
52 Week High 7.775
Market Cap $75,170,311
Shares 35,795,386
Float 20,113,204
Enterprise Value $33,802,713
Volume 3,617
Av. Daily Volume 34,634
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/24/2022
EF Hutton Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/19/2021

Latest News

  1. MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022.

    "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient…

    View Full Article
  2. Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells 
    Without Using Feeder Cells
    Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy

    Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells
    That Circumvents Need for Magnetic Beads
    For Adoptive Cell Therapy for Autoimmune and Inflammatory Diseases

    MIRAMAR, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, is presenting two groups of novel immunotherapeutics created with its…

    View Full Article
  3. Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer

    Debut of preclinical data related to age-associated diseases

    MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology ("CEB-2022") taking place in Boston, Massachusetts on April 18-20…

    View Full Article
  4. $56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023

    FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications

    Publication of Three Pivotal Scientific Papers in Peer-Reviewed Journals

    MIRAMAR, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its fourth quarter and full year ended December 31, 2021.

    Dr. Hing C. Wong, the Founder and CEO of HCW Biologics…

    View Full Article
  5. MIRAMAR, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, will participate in Maxim's 2022 Virtual Growth Conference being held March 28 – 30, 2022.

    Members of the HCW Biologics' management team will provide an overview of the Company highlighting the status of its internal pipeline, upcoming milestones for multiple clinical trials for difficult-to-treat cancer indications, and its clinical development strategy to expand to the treatment of other age-related diseases associated with…

    View Full Article
View All HCW Biologics Inc. News